Free Trial

Scancell (SCLP) Competitors

Scancell logo
GBX 11.04 +0.04 (+0.36%)
As of 05:43 AM Eastern

SCLP vs. PRTC, HZD, FARN, VRP, AVCT, ARIX, CIR, BVXP, 4BB, and TILS

Should you be buying Scancell stock or one of its competitors? The main competitors of Scancell include PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Avacta Group (AVCT), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), and Tiziana Life Sciences (TILS). These companies are all part of the "biotechnology" industry.

Scancell vs. Its Competitors

Scancell (LON:SCLP) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

PureTech Health has a consensus price target of GBX 455, indicating a potential upside of 245.22%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Scancell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scancell
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
PureTech Health
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

46.5% of Scancell shares are held by institutional investors. Comparatively, 79.9% of PureTech Health shares are held by institutional investors. 5.0% of Scancell shares are held by company insiders. Comparatively, 15.9% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Scancell has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Scancell has higher earnings, but lower revenue than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ScancellN/AN/A-£6.75M-£0.65-16.93
PureTech Health£521.32K759.42-£91.86M-£24.38-5.41

In the previous week, Scancell had 8 more articles in the media than PureTech Health. MarketBeat recorded 9 mentions for Scancell and 1 mentions for PureTech Health. Scancell's average media sentiment score of 0.79 beat PureTech Health's score of 0.00 indicating that Scancell is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scancell
2 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PureTech Health
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Scancell has a net margin of 0.00% compared to PureTech Health's net margin of -17,620.94%. Scancell's return on equity of 98.74% beat PureTech Health's return on equity.

Company Net Margins Return on Equity Return on Assets
ScancellN/A 98.74% -45.28%
PureTech Health -17,620.94%-21.15%-13.39%

Summary

PureTech Health beats Scancell on 9 of the 15 factors compared between the two stocks.

Get Scancell News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLP vs. The Competition

MetricScancellBiotechnology IndustryMedical SectorLON Exchange
Market Cap£114.34M£133.95M£5.48B£3.07B
Dividend YieldN/A3.74%3.99%5.03%
P/E Ratio-16.933.7629.94166.65
Price / SalesN/A4,236.63398.94315,722.17
Price / Cash7.8613.1935.9427.96
Price / Book-28.3238.648.104.50
Net Income-£6.75M-£90.30M£3.26B£5.90B
7 Day Performance5.19%0.90%0.68%1.35%
1 Month Performance10.40%3.31%2.46%3.69%
1 Year Performance-36.91%179.74%27.69%56.84%

Scancell Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCLP
Scancell
N/AGBX 11.04
+0.4%
N/A-37.5%£114.34MN/A-16.9351
PRTC
PureTech Health
1.9556 of 5 stars
GBX 143
-1.2%
GBX 455
+218.2%
-19.9%£429.55M£521.32K-5.87300
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63M-33.55416
FARN
Faron Pharmaceuticals Oy
N/AGBX 186.50
-5.3%
N/A+30.7%£250.38MN/A-4.9934Gap Up
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Gap Up
AVCT
Avacta Group
N/AGBX 52.49
-1.0%
N/A-31.1%£199.42M£26.29M-6.75120News Coverage
Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down
BVXP
Bioventix
N/AGBX 2,650
-0.9%
N/A-44.0%£138.76M£13.65M17.1412Positive News
4BB
4basebio
1.9892 of 5 stars
GBX 941
-3.0%
GBX 1,600
+70.0%
-25.0%£120.54M£311K-1,206.41101Gap Down
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60M-3.5911

Related Companies and Tools


This page (LON:SCLP) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners